drugset / Trial / NCT00981903
Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer
Non-randomizedSingle-groupOpen-labelPrevention
Summary
In this study the investigators will determine the safety and effectiveness of Tinzaparin in preventing blood clots for up to 12 months of treatment.
Timeline
- Start
- 2005-07
- Primary completion
- 2012-10
- Completion
- 2015-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tinzaparin | Other / unclassified | 175 iu/kg | Subcutaneous |